ELCO Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ELCO Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,042	Closed	-$215K	–	157
2025 Q1	$215K	Buy	+3,042	New	+$205K	0.12%	136

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ELCO Management's BMRN Position: Q2 2025 in Review

ELCO Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,042 shares — an estimated $215K sold.

ELCO Management first reported a position in BMRN in Q1 2025 and held it in 1 quarter. The position peaked at $215K in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

ELCO Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
ELCO Management sold 3,042 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $215K.
ELCO Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 1 quarter.
ELCO Management's BioMarin Pharmaceuticals position peaked at $215K in Q1 2025.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on ELCO Management's 13F filing for Q2 2025, filed 4 Aug 2025.